None listed
Conditions
Interventions
Drug, Procedure/Surgery : Injection drug: Meditoxin® (Botulinum toxin)
Dose: Parotid gland (25 IU), Submandibular gland (8IU)
Number and Duration: Once
Injection pathway: Direct injection into salivar
Sponsors
Bundang CHA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The enrolled patient should comply with all of the following criteria. 1) Men and women over 20 and under 70 2) The patient who have experienced symptoms for more than 6 months 3) The patient who repeat 3 or more episodes of sialoadenitis 4) The patient who voluntarily decided to participate and signed the consent form before starting this clinical trial
Exclusion criteria
Exclusion criteria: Patients who fall under any of the following criteria are not allowed to register for this clinical trial. 1) Patients who have been confirmed to have a stone or tumor in the salivary gland by CT or MRI 2) Patients with salivary glands hypertrophy without pain or pressure sense 3) Patients who participated in other clinical trials within last 1 month 4) Patients with less than a longer period of five times the half-life of medicines in previous clinical trials 5) Patient who have the contraindication of Meditoxin 6) In addition to the above, patients who are deemed inappropriate for this trial by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Questionaire (frequency and intensity of pain, frequency and intensity of swelling);SPECT-CT (Single Photon Emission Computed Tomography-Computed Tomography) | — |
Secondary
| Measure | Time frame |
|---|---|
| Salivary flow test | — |
Countries
Korea, Republic of
Contacts
Public ContactJin Cheon
Bundang CHA General Hospital
Outcome results
None listed